Improving diagnosis of cardiovascular, cancer, and neurological diseases using machine learning
Official title: This is a Human Analytics Longitudinal Observational (HALO) Study. A Phase I Study to Analyze All Available Biomarkers and Determinants of Health to Increase Diagnostic Accuracy While Reducing the Time to Diagnosis of Disease.
Run by HALO Diagnostics · NCT05423860 · Data updated 2026-11-12
This study is testing if using machine learning can help doctors diagnose heart problems, cancer, and brain injuries faster and more accurately in patients who haven't started treatment yet.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 45 Years to 90 Years |
| Sex | Men only |
| Enrollment | 2000 (estimated) |
| Sponsor | HALO Diagnostics Industry-sponsored |
| Locations | 1 site (Indian Wells, California) |
| Status | Recruiting |
| Started | March 16, 2022 |
| Main results expected | March 2027 |
| Study ends | March 2037 |
| Registry record updated | October 14, 2022 |
| Trial ID | NCT05423860 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include treatment-naïve males aged 45 and older diagnosed with prostate adenocarcinoma at specific clinical stages.
✕Probably not a fit
Patients with conditions incompatible with MRI or severe lower urinary tract issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to discover, optimize, standardize, and validate clinical measures and biomarkers for diagnosing cardiovascular diseases, cancer, dementia, and traumatic brain injury. By utilizing electronic medical records and advanced data analysis techniques, the study seeks to enhance diagnostic accuracy and reduce the time to diagnosis through machine learning algorithms. Additionally, it will develop multivariate biomarker risk scores to predict the future development of these diseases and direct participants to relevant clinical trials. The focus is on treatment-naïve patients with specific conditions, particularly prostate adenocarcinoma.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of serious diseases, improving patient outcomes.
How similar studies have gone: Other studies utilizing machine learning for diagnostic purposes have shown promise, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Treatment Naïve patients: * Male, 45 years of age or older. * Diagnosis of prostate adenocarcinoma. * Clinical stage T1c or T2a. * Gleason score of 7 (3+4 or 4+3) or less. * Three or fewer biopsy cores with prostate cancer. * PSA density not exceeding 0.375. * One, two, or three tumor suspicious regions identified on multiparametric MRI. * Negative radiographic indication of extra-capsular extent. * Karnofsky performance status of at least 70. * Estimated survival of 5 years or greater, as determined by treating physician. * Tolerance for anesthesia/sedation. * Ability to give informed consent. * At least 6 weeks since any previous prostate biopsy. * MR-guided biopsy confirmation of one or more MRI-visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less. Salvage candidates will be accepted upon physician referral. Exclusion Criteria: * Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI. * Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater * History of other primary non-skin malignancy within previous three years. * Diabetes * Smoker
Where it's running
-
Desert Medical Imaging
Indian Wells, California, United States Recruiting
Study contacts
- Principal investigator: Christopher R. Hancock, MD — HALO Diagnostics
- Study coordinator: Christopher R Hancock, MD,MBA
- Email: chris.hancock@halodx.com
- Phone: 760-776-8989
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
100-Year Human Aging and Longevity Tracking Program
This project will follow adults over their lifetimes to see if repeated health tests can predict lifespan, causes of death, serious disease, and loss of function.
-
Virtual registry for menopause and perimenopause in Australia
This study is creating an online registry to collect information from Australian women about their experiences with menopause and perimenopause to help improve healthcare and support for them.
-
Comparing advice on moderate drinking versus abstention for health outcomes
This study is testing whether giving advice on moderate drinking or complete abstention is better for the health of adults over 50 in Spain.
-
Comparing two group wellness programs for people with brain injuries and their caregivers
This study is testing two different online wellness programs to see if they can help people with brain injuries and Alzheimer's disease, along with their caregivers, feel better and improve their quality of life.
-
Evaluating the effects of statins on older adults' health
This study is testing whether a cholesterol-lowering medication called atorvastatin can help older adults aged 75 and up stay healthier and avoid issues like dementia and disability.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.